Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AL-4943A (Pazeo) in Allergic Conjunctivitis
NCT01479374Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2012
- Primary completion
- Mar 2012
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of olopatadine in allergic conjunctivitis (AC), sponsored by Alcon Inc.. Started Jan 2012; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01479374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01479374.